Xenon pharmaceuticals presents data from phase 2 x-nova clinical trial of azetukalner in major depressive disorder at the american society of clinical psychopharmacology 2024 annual meeting

Vancouver, british columbia, may 28, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (xen1101) clinical data in major depressive disorder (mdd) at the american society of clinical psychopharmacology (ascp) 2024 annual meeting in miami, fl.
NOVA Ratings Summary
NOVA Quant Ranking